MA46981A - Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine - Google Patents

Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Info

Publication number
MA46981A
MA46981A MA046981A MA46981A MA46981A MA 46981 A MA46981 A MA 46981A MA 046981 A MA046981 A MA 046981A MA 46981 A MA46981 A MA 46981A MA 46981 A MA46981 A MA 46981A
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
bromodomain inhibitors
bromodomain
inhibitors
benzimidazole
Prior art date
Application number
MA046981A
Other languages
English (en)
Inventor
Rino Antonio Bit
John Alexander Brown
Philip G Humphreys
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA46981A publication Critical patent/MA46981A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
MA046981A 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine MA46981A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504689.9A GB201504689D0 (en) 2015-03-19 2015-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
MA46981A true MA46981A (fr) 2019-10-09

Family

ID=53052091

Family Applications (2)

Application Number Title Priority Date Filing Date
MA041778A MA41778A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA046981A MA46981A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA041778A MA41778A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Country Status (35)

Country Link
US (2) US10442786B2 (fr)
EP (2) EP3549939A1 (fr)
JP (1) JP6419990B2 (fr)
KR (1) KR102072850B1 (fr)
CN (1) CN107635989B (fr)
AR (1) AR103934A1 (fr)
AU (1) AU2016232217B2 (fr)
BR (1) BR112017019779B1 (fr)
CA (1) CA2979504C (fr)
CL (1) CL2017002332A1 (fr)
CO (1) CO2017009992A2 (fr)
CR (1) CR20170430A (fr)
CY (1) CY1121855T1 (fr)
DK (1) DK3271349T3 (fr)
DO (1) DOP2017000213A (fr)
EA (1) EA033594B1 (fr)
ES (1) ES2735417T3 (fr)
GB (1) GB201504689D0 (fr)
HR (1) HRP20191186T1 (fr)
HU (1) HUE044414T2 (fr)
IL (1) IL254318B (fr)
LT (1) LT3271349T (fr)
MA (2) MA41778A (fr)
ME (1) ME03485B (fr)
MX (1) MX2017012023A (fr)
PE (1) PE20180032A1 (fr)
PH (1) PH12017501620A1 (fr)
PL (1) PL3271349T3 (fr)
PT (1) PT3271349T (fr)
RS (1) RS59056B1 (fr)
SG (1) SG11201707356QA (fr)
SI (1) SI3271349T1 (fr)
TW (1) TW201706257A (fr)
UY (1) UY36589A (fr)
WO (1) WO2016146738A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
MX2018001751A (es) 2015-08-11 2018-08-01 Neomed Inst Dihidroquinolinonas aril-sustituidas, su preparacion y su uso como farmaceuticos.
WO2017024412A1 (fr) 2015-08-12 2017-02-16 Neomed Institute Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
WO2017066876A1 (fr) 2015-10-21 2017-04-27 Neomed Institute Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments
WO2017127930A1 (fr) 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
GB201614939D0 (en) 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
EP3750885A4 (fr) * 2018-02-06 2021-10-27 Shanghai Haihe Pharmaceutical Co., Ltd. Composé présentant une activité inhibitrice de bet, son procédé de préparation et son utilisation
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
WO2020190780A1 (fr) * 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibition de la protéine de liaison à un élément sensible à l'amp cyclique (creb)
WO2020219168A1 (fr) * 2019-04-24 2020-10-29 Convergene, Llc Inhibiteurs de bromodomaines à petites molécules et leurs utilisations
US20220227709A1 (en) * 2019-04-29 2022-07-21 The Board Of Regents Of The University Of Texas System Compositions and methods for treating schistosoma infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
EA016264B1 (ru) 2006-03-31 2012-03-30 Янссен Фармацевтика Н.В. Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н
JP2013508461A (ja) * 2009-10-27 2013-03-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (fr) * 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EP3010918B1 (fr) * 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate

Also Published As

Publication number Publication date
LT3271349T (lt) 2019-07-10
CN107635989A (zh) 2018-01-26
EA033594B1 (ru) 2019-11-07
HUE044414T2 (hu) 2019-10-28
EP3271349A1 (fr) 2018-01-24
PL3271349T3 (pl) 2019-10-31
MX2017012023A (es) 2018-01-30
US10442786B2 (en) 2019-10-15
PH12017501620A1 (en) 2018-02-12
US20200039953A1 (en) 2020-02-06
ME03485B (fr) 2020-01-20
TW201706257A (zh) 2017-02-16
US20180044317A1 (en) 2018-02-15
PE20180032A1 (es) 2018-01-09
EP3549939A1 (fr) 2019-10-09
UY36589A (es) 2016-10-31
CN107635989B (zh) 2020-12-08
DOP2017000213A (es) 2017-10-15
HRP20191186T1 (hr) 2019-10-04
EP3271349B1 (fr) 2019-05-15
CY1121855T1 (el) 2020-07-31
SG11201707356QA (en) 2017-10-30
CO2017009992A2 (es) 2018-01-05
US11053212B2 (en) 2021-07-06
PT3271349T (pt) 2019-08-19
AU2016232217A1 (en) 2017-10-12
GB201504689D0 (en) 2015-05-06
BR112017019779B1 (pt) 2023-10-03
CA2979504A1 (fr) 2016-09-22
JP2018507903A (ja) 2018-03-22
IL254318A0 (en) 2017-11-30
AR103934A1 (es) 2017-06-14
SI3271349T1 (sl) 2019-08-30
CA2979504C (fr) 2023-10-10
MA41778A (fr) 2018-01-24
RS59056B1 (sr) 2019-08-30
ES2735417T3 (es) 2019-12-18
BR112017019779A2 (pt) 2018-05-22
KR102072850B1 (ko) 2020-02-03
IL254318B (en) 2019-08-29
AU2016232217B2 (en) 2019-04-04
WO2016146738A1 (fr) 2016-09-22
KR20170129871A (ko) 2017-11-27
CL2017002332A1 (es) 2018-03-16
JP6419990B2 (ja) 2018-11-07
DK3271349T3 (da) 2019-08-05
CR20170430A (es) 2017-11-08
EA201791973A1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
DK3319956T3 (da) Substituerede oxopyridinderivater
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
MA53352A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA40770A (fr) Dérivés d'imidazoles pentacyclic fusionnés
DK3286177T3 (da) Quinolinderivater som tam rtk-inhibitorer
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1